137 related articles for article (PubMed ID: 17507814)
41. Salvage robotic-assisted radical prostatectomy: initial results and early report of outcomes.
Boris RS; Bhandari A; Krane LS; Eun D; Kaul S; Peabody JO
BJU Int; 2009 Apr; 103(7):952-6. PubMed ID: 19076132
[TBL] [Abstract][Full Text] [Related]
42. Mediastinal lymph nodes in patients with non-small cell lung cancer: preliminary experience with diffusion-weighted MR imaging.
Hasegawa I; Boiselle PM; Kuwabara K; Sawafuji M; Sugiura H
J Thorac Imaging; 2008 Aug; 23(3):157-61. PubMed ID: 18728541
[TBL] [Abstract][Full Text] [Related]
43. Mixed-histologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis: feasibility of endoscopic submucosal dissection.
Hanaoka N; Tanabe S; Mikami T; Okayasu I; Saigenji K
Endoscopy; 2009 May; 41(5):427-32. PubMed ID: 19418397
[TBL] [Abstract][Full Text] [Related]
44. Pelvic lymph node irradiation for prostate cancer: who, why, and when?
Wang D; Lawton C
Semin Radiat Oncol; 2008 Jan; 18(1):35-40. PubMed ID: 18082586
[TBL] [Abstract][Full Text] [Related]
45. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue.
Heerschap A; Jager GJ; van der Graaf M; Barentsz JO; de la Rosette JJ; Oosterhof GO; Ruijter ET; Ruijs SH
Anticancer Res; 1997; 17(3A):1455-60. PubMed ID: 9179183
[TBL] [Abstract][Full Text] [Related]
46. MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer.
Hasumi M; Suzuki K; Oya N; Ito K; Kurokawa K; Fukabori Y; Yamanaka H
Anticancer Res; 2002; 22(2B):1205-8. PubMed ID: 12168926
[TBL] [Abstract][Full Text] [Related]
47. Prostate cancer metastasis to supraclavicular lymph node.
Hobdy EM; Shafi NQ; Kummar S
Clin Adv Hematol Oncol; 2004 Apr; 2(4):223-4; discussion 224. PubMed ID: 16163185
[No Abstract] [Full Text] [Related]
48. Cervical lymph node enlargement on the right side as the initial manifestation of metastatic prostate cancer.
Ozgür A; Ilker Y; Türkeri LN
Arch Esp Urol; 2003 Sep; 56(7):859-61. PubMed ID: 14595895
[TBL] [Abstract][Full Text] [Related]
49. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T.
Scheenen TW; Gambarota G; Weiland E; Klomp DW; Fütterer JJ; Barentsz JO; Heerschap A
Magn Reson Med; 2005 Jun; 53(6):1268-74. PubMed ID: 15906304
[TBL] [Abstract][Full Text] [Related]
50. [Imaging procedures to diagnose prostate cancer].
Seitz M; Scher B; Scherr M; Tilki D; Schlenker B; Gratzke C; Schipf A; Stanislaus P; Müller-Lisse U; Reich O; Stief C
Urologe A; 2007 Oct; 46(10):W1435-46; quiz W1447-8. PubMed ID: 17665166
[TBL] [Abstract][Full Text] [Related]
51. A case of prostate cancer with a large abdominal mass effectively treated with a high dose of diethylstilbestrol-diphosphate.
Wakisaka M; Takagishi H
Hinyokika Kiyo; 1993 Sep; 39(9):849-51. PubMed ID: 8213382
[TBL] [Abstract][Full Text] [Related]
52. Proton MR T2 maps correlate with the citrate concentration in the prostate.
Liney GP; Lowry M; Turnbull LW; Manton DJ; Knowles AJ; Blackband SJ; Horsman A
NMR Biomed; 1996 Apr; 9(2):59-64. PubMed ID: 8887369
[TBL] [Abstract][Full Text] [Related]
53. A feasibility study to investigate the use of thin-plate splines to account for prostate deformation.
Venugopal N; McCurdy B; Hnatov A; Dubey A
Phys Med Biol; 2005 Jun; 50(12):2871-85. PubMed ID: 15930608
[TBL] [Abstract][Full Text] [Related]
54. [Prostate neoplasms--tumor grading and magnetic resonance spectroscopy].
Rofo; 2005 Oct; 177(10):1342. PubMed ID: 16170697
[No Abstract] [Full Text] [Related]
55. [Cancer of the prostate with predominant lymphatic manifestation. Apropos of 2 cases].
Herer B; Waligora J; Delfraissy JF; Dormont J
J Urol (Paris); 1987; 93(8):475-7. PubMed ID: 3440840
[TBL] [Abstract][Full Text] [Related]
56. The role of lymphadenectomy in prostate cancer.
Burkhard FC; Studer UE
Urol Oncol; 2004; 22(3):198-202; discussion 202-4. PubMed ID: 15271316
[No Abstract] [Full Text] [Related]
57. In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma.
Bourne RM; Stanwell P; Stretch JR; Scolyer RA; Thompson JF; Mountford CE; Lean CL
Eur J Radiol; 2005 Mar; 53(3):506-13. PubMed ID: 15741026
[TBL] [Abstract][Full Text] [Related]
58. Leakage of metabolites from tissue biopsies can result in large errors in quantitation by MRS.
Bourne R; Dzendrowskyj T; Mountford C
NMR Biomed; 2003 Apr; 16(2):96-101. PubMed ID: 12730950
[TBL] [Abstract][Full Text] [Related]
59. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T.
Cunningham CH; Vigneron DB; Marjanska M; Chen AP; Xu D; Hurd RE; Kurhanewicz J; Garwood M; Pauly JM
Magn Reson Med; 2005 May; 53(5):1033-9. PubMed ID: 15844147
[TBL] [Abstract][Full Text] [Related]
60. Staging of M0 prostatic adenocarcinoma: how aggressive should one be?
Olsson CA
Prog Clin Biol Res; 1984; 153():455-67. PubMed ID: 6473408
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
